Details for New Drug Application (NDA): 202276
✉ Email this page to a colleague
The generic ingredient in STENDRA is avanafil. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the avanafil profile page.
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Apr 27, 2012 | TE: | AB | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Apr 27, 2012 | TE: | AB | RLD: | Yes | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Apr 27, 2012 | TE: | AB | RLD: | Yes | ||||
Expired US Patents for NDA 202276
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | 6,656,935 | ⤷ Start Trial |
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | 7,501,409 | ⤷ Start Trial |
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | 7,501,409 | ⤷ Start Trial |
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | 6,656,935 | ⤷ Start Trial |
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | 7,501,409 | ⤷ Start Trial |
| Vivus Llc | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | 6,656,935 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
